Plasma chitotriosidase in male Fabry patients: a marker for monitoring lipid-laden macrophages and their correction by enzyme replacement therapy (Q83961413)

From Wikidata

Jump to navigation Jump to search

scientific article published on 09 June 2006

Language	Label	Description	Also known as
English	Plasma chitotriosidase in male Fabry patients: a marker for monitoring lipid-laden macrophages and their correction by enzyme replacement therapy	scientific article published on 09 June 2006

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16765076%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Plasma chitotriosidase in male Fabry patients: a marker for monitoring lipid-laden macrophages and their correction by enzyme replacement therapy (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16765076%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16765076%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

author name string

Vedder AC

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16765076%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Cox-Brinkman J

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16765076%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Hollak CE

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16765076%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Linthorst GE

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16765076%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Groener JE

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16765076%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Helmond MT

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16765076%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Scheij S

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16765076%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

publication date

9 June 2006

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16765076%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Molecular Genetics and Metabolism

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16765076%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

89

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16765076%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

239-244

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16765076%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16765076%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Enzymatic Defect in Fabry's Disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.04.013

7 January 2021

Fabry's Disease: Alpha-Galactosidase Deficiency

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.04.013

7 January 2021

Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.04.013

7 January 2021

Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher's disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.04.013

7 January 2021

Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.04.013

7 January 2021

Enzyme replacement therapy in Fabry disease: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.04.013

7 January 2021

Fabry disease: overall effects of agalsidase alfa treatment

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.04.013

7 January 2021

Long-term safety and efficacy of enzyme replacement therapy for Fabry disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.04.013

7 January 2021

Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.04.013

7 January 2021

The relationship of vascular glycolipid storage to clinical manifestations of Fabry disease: a cross-sectional study of a large cohort of clinically affected heterozygous women

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.04.013

7 January 2021

Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.04.013

7 January 2021

Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.04.013

7 January 2021

Elevated plasma chitotriosidase activity in various lysosomal storage disorders.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.04.013

7 January 2021

Plasma chitotriosidase and CCL18: early biochemical surrogate markers in type B Niemann-Pick disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.04.013

7 January 2021

The expanding spectrum of disorders with elevated plasma chitotriosidase activity: an update

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.04.013

7 January 2021

The Mainz Severity Score Index: a new instrument for quantifying the Anderson-Fabry disease phenotype, and the response of patients to enzyme replacement therapy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.04.013

7 January 2021

Transglycosidase activity of chitotriosidase: improved enzymatic assay for the human macrophage chitinase.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.04.013

7 January 2021

The human chitotriosidase gene. Nature of inherited enzyme deficiency

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.04.013

7 January 2021

Plasma and metabolic abnormalities in Gaucher's disease.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.04.013

7 January 2021

Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.04.013

7 January 2021

Recombinant enzyme therapy for Fabry disease: absence of editing of human alpha-galactosidase A mRNA.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.04.013

7 January 2021

Ultrastructural and biochemical liver analyses in Fabry's disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.04.013

7 January 2021

Strong induction of members of the chitinase family of proteins in atherosclerosis: chitotriosidase and human cartilage gp-39 expressed in lesion macrophages.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.04.013

7 January 2021

Monitoring enzyme replacement therapy in Fabry disease--role of urine globotriaosylceramide.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.04.013

7 January 2021

Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.04.013

7 January 2021

Clinically relevant therapeutic endpoints in type I Gaucher disease.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.04.013

7 January 2021

X-chromosome inactivation and human genetic disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.04.013

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.YMGME.2006.04.013

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16765076%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16765076%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q83961413&oldid=1746097369"